ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
50 announcements with these filters
Krsnaa Diagnostics Limited announced a board meeting scheduled for August 13, 2026, to discuss financial results for the quarter ending June 30, 2026, and fundraising proposals.
Krsnaa Diagnostics entered a PPP agreement with the Himachal Pradesh government to operate CT scan facilities at 34 health institutions, expanding from its previous 12 locations.
Krsnaa Diagnostics disclosed voting results for its postal ballot. Resolutions for re-appointing and appointing independent directors were passed with requisite majority.
ICRA has reaffirmed Krsnaa Diagnostics' credit ratings for bank facilities totaling ₹304.15 Crore. Long-term facilities are rated [ICRA]A(Stable) and short-term rated [ICRA]A1.
Krsnaa Diagnostics Limited issued a postal ballot notice for director re-appointments and commission approvals. Shareholders can vote electronically from June 5 to July 4, 2026.
Krsnaa Diagnostics reports 8% revenue growth and crossing ₹100cr PAT milestone in FY26, driven by PPP scaling and a sixfold growth in retail diagnostics.
Krsnaa Diagnostics reported FY26 revenue of ₹7,728 Mn (up 8% YoY) and PAT of ₹1,013 Mn (up 31% YoY). Strategy focuses on PPP model and aggressive retail expansion.
Krsnaa Diagnostics reported ₹772.8 Crore revenue for FY2026, with PAT growing 31% to ₹101.4 Crore. The company also declared a ₹2 final dividend per share.
Krsnaa Diagnostics filed its FY26 Annual Secretarial Compliance Report. The report confirms full adherence to SEBI regulations with no observed non-compliances or penalties.
Krsnaa Diagnostics recommended a final dividend of ₹2 per equity share for FY 2025-26. The record date and shareholder meeting for final approval are pending.
Krsnaa Diagnostics Ltd reported revenue from operations of ₹192.6 Cr (+3.5% YoY) and net profit of ₹41.7 Cr (+101.4% YoY) for Q4 FY26.
Krsnaa Diagnostics approved FY2026 financial results and recommended a final dividend of ₹2 per share. The company reported consolidated annual profit of ₹101.43 Crore.
Krsnaa Diagnostics received income tax demand notices totaling ₹11.31 Crore for two assessment years. The company is contesting these orders before appellate forums.
Krsnaa Diagnostics scheduled a board meeting for May 25, 2026. Directors will consider audited annual financial results and a potential final dividend declaration.
Krsnaa Diagnostics scheduled a board meeting for May 25, 2026. Directors will approve FY2026 audited financial results and recommend a potential dividend.
Krsnaa Diagnostics Ltd confirmed it does not fall under the 'Large Corporate' category as of March 31, 2026, per SEBI debt-raising norms. The company reported outstanding borrowings of ₹479.75 Crore and holds an 'A' credit rating from ICRA Limited.
Krsnaa Diagnostics Limited announced a leadership reorganization effective April 2026. This includes the re-appointment of Chetan Desai and new appointments of Raju Venkatraman, Jessie Paul, and CFO Chandra Prakash Singh. Simultaneously, Pallavi Bhatevara, Rajiva Ranjan Verma, and Chhaya Palrecha will cease their roles. The changes aim to strengthen governance and strategic expertise.
Krsnaa Diagnostics announced its Board Meeting outcome involving the appointment of Mr. Raju Venkatraman and Ms. Lilian Jessie Paul as Independent Directors. Additionally, Mr. Chandra Prakash Singh was named Interim CFO. Several directors completed their tenures, and the Board reconstituted various committees including Audit and Risk Management to strengthen corporate governance effective April 25, 2026.
Krsnaa Diagnostics Ltd announced the approval of Mr. Rajendra Khivraj Mutha's re-appointment as Executive Chairman for five years via postal ballot. The ordinary resolution was passed with a 99.99% majority on April 16, 2026. The remote e-voting results and scrutinizer's report have been submitted to the exchanges.
Krsnaa Diagnostics Ltd submitted its quarterly confirmation certificate under SEBI (Depositories and Participants) Regulations for the period ended March 31, 2026. The certificate, issued by KFin Technologies, confirms compliance regarding the dematerialization of securities. This is a routine regulatory filing with no material impact on business operations.